Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p64
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 64/66)
Character Range: 211269–214190

Schedule 5, entry for Amitriptyline in the form Tablet containing amitriptyline hydrochloride 50 mg
omit from the column headed "Brand": APO-Amitriptyline 50
[421] Schedule 5, entry for Atenolol
omit from the column headed "Brand": APO-Atenolol
[422] Schedule 5, entry for Bosentan in each of the forms: Tablet 125 mg (as monohydrate); and Tablet 62.5 mg (as monohydrate)
omit from the column headed "Brand": BOSLEER
[423] Schedule 5, entry for Calcitriol
(a) omit from the column headed "Brand": APO-Calcitriol
(b) omit from the column headed "Brand": Kosteo
[424] Schedule 5, after entry for Celecoxib in the form Capsule 200 mg [GRP-19623]
insert:
Choriogonadotropin alfa  GRP-29227  Solution for injection 250 micrograms in 0.5 mL pre-filled pen             Injection  Ovidrel
Choriogonadotropin alfa  GRP-29227  Solution for injection 250 micrograms in 0.5 mL pre-filled syringe (S19A)  Injection  Ovidrel (USA)

[425] Schedule 5, entry for Ciprofloxacin in each of the forms: Tablet 750 mg (as hydrochloride); Tablet 500 mg (as hydrochloride); and Tablet 250 mg (as hydrochloride)
omit from the column headed "Brand": APX-Ciprofloxacin
[426] Schedule 5, entry for Citalopram in each of the forms: Tablet 40 mg (as hydrobromide); Tablet 20 mg (as hydrobromide); and Tablet 10 mg (as hydrobromide)
insert in alphabetical order in the column headed "Brand": CITALOPRAM-WGR
[427] Schedule 5, entry for Diazepam in each of the forms: Tablet 5 mg; and Tablet 2 mg
omit from the column headed "Brand": APO-Diazepam
[428] Schedule 5, entry for Diclofenac in each of the forms: Tablet (enteric coated) containing diclofenac sodium 50 mg; and Tablet (enteric coated) containing diclofenac sodium 25 mg
omit from the column headed "Brand": APO-Diclofenac
[429] Schedule 5, entry for Entecavir in each of the forms: Tablet 0.5 mg (as monohydrate); and Tablet 1 mg (as monohydrate)
omit from the column headed "Brand": ENTECLUDE
[430] Schedule 5, entry for Fluconazole in the form Capsule 200 mg
insert in alphabetical order in the column headed "Brand": FLUCONAZOLE-WGR
[431] Schedule 5, entry for Fulvestrant
insert in alphabetical order in the column headed "Brand": FULVESTRANT-AFT
[432] Schedule 5, entry for Gliclazide in the form Tablet 80 mg
(a) omit from the column headed "Brand": APO-Gliclazide
(b) omit from the column headed "Brand": Glyade

[433] Schedule 5, entry for Ibuprofen
omit from the column headed "Brand": MEDICHOICE Ibuprofen 400 mg
[434] Schedule 5, entry for Imatinib in the form Capsule 400 mg (as mesilate)
insert in alphabetical order in the column headed "Brand": ARX-IMATINIB
[435] Schedule 5, entry for Irbesartan in the form Tablet 75 mg
omit from the column headed "Brand": Karvea
[436] Schedule 5, entry for Itraconazole
omit from the column headed "Brand": APO-Itraconazole
[437] Schedule 5, entry for Macrogol 3350
omit from the column headed "Brand": Movicol
[438] Schedule 5, entries for